Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Erlangen – page 21

390 clinical trials in Erlangen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erlangen at a glance
390
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

390 trials in Erlangen

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on the Effects of Ribociclib and Endocrine Therapy for Patients with HR-Positive, HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Chronic graft versus host disease

Not recruiting

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Hidradenitis

Not recruiting

Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Pfizer Inc.

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Interstitial lung disease+1

Not recruiting

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
  • Sponsor:Boehringer Ingelheim Espana S.A.

Skin ulcer

Not recruiting

Study on the Effectiveness of Allo-APZ2-CVU for Patients with Long-Term, Non-Healing Venous Leg Ulcers

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Skin-Derived Abcb5-Positive Dermal Mesenchymal Stromal Cells
  • Sponsor:Rheacell GmbH & Co. KG

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Cholangitis sclerosing

Not recruiting

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Multiple system atrophy

Not recruiting

Study of Amlenetug for Patients with Multiple System Atrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AMLENETUG
  • Sponsor:H. Lundbeck A/S

Hidradenitis

Not recruiting

Study on the Effectiveness of AVTX-009 for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AVTX-009
  • Sponsor:Avalo Therapeutics Inc.

Primary mediastinal large B-cell lymphoma

Not recruiting

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Axicabtagene Ciloleucel
  • Sponsor:Universitaet Muenster

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Erlangen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies of new therapies for HR-positive and HER2-negative variants. Additional research encompasses lung cancer and various lymphomas.

  • Advanced/Metastatic Breast Cancer Treatments
  • Non-small Cell Lung Cancer Therapy
  • Lymphoma Treatment Approaches

Studies evaluate novel therapeutic combinations and targeted treatments for improved patient outcomes.

02 Autoimmune Conditions

Comprehensive research into various autoimmune disorders, including lupus erythematosus, psoriasis, and systemic conditions. Studies focus on innovative therapeutic approaches.

  • Cutaneous Lupus Treatment
  • Plaque Psoriasis Management
  • Systemic Sclerosis Research

Trials aim to develop more effective treatments for chronic autoimmune conditions.

03 Neurological Disorders

Clinical investigations focusing on acute cerebral ischemic stroke and multiple system atrophy. Research emphasizes innovative therapeutic approaches for better patient outcomes.

  • Stroke Treatment Development
  • Multiple System Atrophy Management
  • Neurological Disease Interventions

Studies evaluate new therapeutic agents and treatment strategies for neurological conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.